Sanofi has been building up its stocks for six months, with the drugmaker's shortage contingency plans stretching back for more than a year, according to the Wall Street Journal. This move was done in case the European Union and Britain fail to make a Brexit transition deal.
Sanofi has increased its stocks by four weeks to give it a 14 week supply of medicines.
Sanofi sends batches from its two plants in Britain back to its headquarters for quality control purposes. If no deal is made, this would no longer be possible and would necessitate a reduction in its workforce in the United Kingdom, which is nearly 1,800 individuals.
Read the Wall Street Journal report